Shorter Versus Standard Antithyroid Drug Therapy in Graves’ Disease with Lower Baseline Thyrotropin Receptor Antibody (TRAb) Levels: Relapse Outcomes from a Propensity-Weighted Analysis

Thyroid 2026

View at publisher
Authors: Salman Razvi, Mia Holley, Hannah Wheeler, Jonathan Vernazza, Kathryn Stewart, Pearce Shs., Kilimangalam Narayanan, Vasileios Tsatlidis
DOI: 10.1177/10507256261470303
Cited by: 1
References: 17

Abstract

BACKGROUND: The optimal duration of antithyroid drug (ATD) therapy in Graves' disease is uncertain. Although guidelines recommend 12-18 months, shorter courses may be sufficient in selected patients. We evaluated whether ATD duration

Fields of Study & Subjects

Thyroid Disorders and Treatments Ophthalmology and Eye Disorders Diabetes and associated disorders

Publication details

Journal / source
Thyroid
Publisher
SAGE Publications
Volume
36
Issue
9
Pages
961–969
Publication date
21 July 2026
Language
EN